Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer

REFERENCES

• Grabowski, H.; Cockburn, I.; Long, G. The market for follow-on biologics: how will it evolve?. Health Affairs 2006, 25, 1291–1301.
   PubMed Web of Science ®Google Scholar
• Iglehart, J.K. Biotech drugs come of age; policymakers take notice. Health Affairs 2006, 25, 1202–1203.
   Web of Science ®Google Scholar
• Manheim, B.S.Jr.; Granahan, P.; Dow, K.J. “Follow-on biologics”: ensuring continued innovation in the biotechnology industry. Health Affairs 2006, 25, 394–404.
   Web of Science ®Google Scholar
• Robinson, J.C. Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Affairs 2006, 25, 1205–1217.
   Web of Science ®Google Scholar
• Nagle, P.C.; Lugo, T.F.; Nicita, C.A. Defining and characterizing the late-stage biopharmaceutical pipeline. AJMC 2003, 9, S124–S135.
   Google Scholar
• American Cancer Society. Monoclonal Antibodies. Available from http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Monoclonal_Antibody_Therapy_Passive_Immunotherapy.asp (accessed August 12, 2008).
   Google Scholar
• Reichert, J.M.; Valge-Archer, V.E. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007, 6, 349–356.
   PubMed Web of Science ®Google Scholar
• FDA. Drug@FDA. [accessd on October 24, 2008] Available at: http://www.accessdate.fda.gov/scripts/cder/drugsatfda/index.cfm.
   Google Scholar
• Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonoal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344, 783–792.
   PubMed Web of Science ®Google Scholar
• Murdoch, D.; Sager, J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008, 20, 104–111.
   PubMed Web of Science ®Google Scholar
• Stern, M.; Herrmann, R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol-Hematol 2005, 54, 11–29.
   PubMed Web of Science ®Google Scholar
• Reeder, C.E.; Gordon, D. Managing oncology costs. AJMC 2006, 12, S3–S16.
   Google Scholar
• Hillner, B.E.; Smith, T.J. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?. J Clin Oncol 2007, 25, 611–613.
   PubMed Web of Science ®Google Scholar
• Schrag, D. The price tag on progress – chemotherapy for colorectal cancer. N Engl J Med 2004, 351, 317–319. .
   PubMed Web of Science ®Google Scholar
• Hornberger, J.C.; Best, J.H. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005, 103, 1644–1651.
   PubMed Web of Science ®Google Scholar
• Kurian, A.W.; Thompson, R.N.; Gaw, A.F.; Arai, S.; Ortiz, R.; Garber, A.M. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol 2007, 25, 634–641.
   PubMed Web of Science ®Google Scholar
• Starling, N.; Tilden, D.; White, J.; Cunningham, D. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007, 96, 206–212.
   PubMed Web of Science ®Google Scholar
• American College of Surgeons. National Cancer Data Base. Available from http://www.facs.org/cancer/ncdb/index.html (accessed June 15, 2008).
   Google Scholar
• Halpern, M.T.; Bian, J.; Ward, E.M.; Schrag, N.M.; Chen, A.Y. Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer 2007, 110, 403–411.
   PubMed Web of Science ®Google Scholar
• Kennedy, B.J.; Fremgen, A.M.; Menck, H.R. The National Cancer Data Base report on Hodgkin's disease for 1985–1989 and 1990–1994. Cancer 1998, 83, 1041–1047.
   PubMed Web of Science ®Google Scholar
• Stewart, A.K.; Bland, K.I.; McGinnis, L.S.Jr.; Morrow, M.; Eyre, H.J. Clinical highlights from the National Cancer Data Base, 2000. CA: Cancer J Clin 2000, 50, 171–183.
   PubMedGoogle Scholar
• American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society, 2007.
   Google Scholar
• American College of Surgeons. FORDS: Facility Oncology Registry Data Standards 2007. Available from http://www.facs.org/cancer/coc/fords/2007/fordscorrected0707.pdf (accessed June 20, 2008)
   Google Scholar
• Lockyer, C.R.; Gillatt, D.A. BCG immunotherapy for superficial bladder cancer. J R Soc Med 2001, 94, 119–123.
   PubMed Web of Science ®Google Scholar
• Jazirehi, A.R.; Gan, X.H.; De Vos, S.; Emmanouilides, C.; Bonavida, B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003, 2, 1183–1193.
   PubMed Web of Science ®Google Scholar
• CMS 2008 ASP Drug Pricing Files, October 2008. Available from http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/01a_2008aspfiles.asp#TopOfPage (accessed December 21, 2008).
   Google Scholar
• Kabbinavar, F.F.; Hambleton, J.; Mass, R.D.; Hurwitz, H.I.; Bergsland, E.; Sarkar, S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23, 3706–3712.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: American Cancer Society, 2004.
   Google Scholar
• Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005, 23, 1147–1157.
   PubMed Web of Science ®Google Scholar
• Kirkwood, J.M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19, 2370–2380.
   PubMed Web of Science ®Google Scholar
• Porta, C.; Paglino, C.; Imarisio, I.; Bonomi, L. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. Sci World J 2007, 7, 837–849.
   Web of Science ®Google Scholar
• Van Cutsem, E.; Peeters, M.; Verslype, C.; Filez, L.; Haustermans, K.; Janssens, J. The medical treatment of colorectal cancer: actual status and new developments. Hepatogastroenterology 1999, 46, 709–716.
   PubMed Web of Science ®Google Scholar
• Lin, A.; Rugo, H.S. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol 2007, 8, 47–60.
   PubMedGoogle Scholar
• Chen, A.Y.; Halpern, M.T.; Schrag, N.M.; Stewart, A.; Leitch, M.; Ward, E. Disparities and trends in receipt of sentinel lymph node biopsy among early stage female breast cancer patients. J Natl Cancer Inst 2008, 100, 462–474.
   PubMed Web of Science ®Google Scholar
• Richardson, L.C.; Tian, L.; Voti, L.; Hartzema, A.G.; Reis, I.; Fleming, L.E.; Mackinnon, J. The roles of teaching hospitals, insurance status, and race/ethnicity in receipt of adjuvant therapy for regional-stage breast cancer in Florida. Am J Public Health 2006, 96, 160–166.
   PubMed Web of Science ®Google Scholar
• Ward, E.; Halpern, M.T.; Schrag, N.; Cokkinides, V.; Desantis, C.; Bandi, P.; Siegel, R.; Stewart, A.; Jemal, A. Association of insurance with cancer care utilization and outcomes. CA: Cancer J Clin 2008, 58, 9–31.
   PubMed Web of Science ®Google Scholar
• Schoen, C.; Doty, M.M.; Collins, S.R.; Holmgren, A.L. Insured but not protected: how many adults are underinsured?. Health Affairs 2005, (Suppl) Web Exclusives: W5-289-W5-302.
   Web of Science ®Google Scholar
• Shih, Y.C.T. Economic of cancer in the elderly population. Institute of Medicine Cancer in Elderly Population: Workshop Proceeding.Washington, DC: The National Academies Press, 2007.
   Google Scholar